Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Maxcyte's Change in Accured Expenses fell 361.1% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 131826.92%. This contributed to the annual value of -$1.9 million for FY2024, which is 15790.28% down from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Change in Accured Expenses is $2.0 million, which was down 361.1% from $249000.0 recorded in Q2 2025.
  • Maxcyte's 5-year Change in Accured Expenses high stood at $2.6 million for Q3 2023, and its period low was -$5.6 million during Q1 2025.
  • In the last 5 years, Maxcyte's Change in Accured Expenses had a median value of $249000.0 in 2025 and averaged $52257.9.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 108362.63% in 2023, then plummeted by 36780.77% in 2024.
  • Maxcyte's Change in Accured Expenses (Quarter) stood at $2.5 million in 2021, then plummeted by 111.3% to -$285100.0 in 2022, then skyrocketed by 707.51% to $1.7 million in 2023, then tumbled by 126.73% to -$463000.0 in 2024, then soared by 532.4% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $249000.0 for Q2 2025, and -$5.6 million during Q1 2025.